Delivering Advanced Therapeutics
CP046 Nasal Teriparatide (Parathyroid Hormone PTH 1-34)
CP046 is a nasal spray formulation of teriparatide (parathyroid hormone or PTH 1-34) being developed in collaboration with the University of Nottingham for the treatment of osteoporosis.
Osteoporosis affects an estimated 75 million people in Europe, the USA and Japan, affecting approximately one-tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and two-thirds of women aged 90. The reduction in bone density associated with osteoporosis increases the risk of fragility fractures, particularly of the spine, hip and wrist with an estimated cost to the NHS of >£2bn per annum in the UK alone. Due to its correlation with age, as the population ages this is expected to increase considerably.
Teriparatide is the only anabolic drug available to treat osteoporosis - increasing bone deposition as opposed to reducing bone resorption. Teriparatide is currently injected daily by patients with severe osteoporosis with the aim of reducing bone fractures (particularly of the spine, wrist and hip) and subsequent hospitalisation. Not only will CP046 (nasal teriparatide) be expected to improve patient compliance - as it is non-invasive and intranasal administration relatively simple compared with subcutaneous injection - but CP046 may also be expected to increase efficacy as the pharmacological effects of teriparatide are dependent on its pharmacokinetics.
CP046 is being developed using Critical Pharmaceuticals CriticalSorb technology.